Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Nov 27 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-2.96 Insider Own49.72% Shs Outstand27.43M Perf Week-11.20%
Market Cap30.56M Forward P/E- EPS next Y-2.71 Insider Trans0.00% Shs Float13.84M Perf Month-46.63%
Income-81.22M PEG- EPS next Q-0.73 Inst Own25.23% Short Float / Ratio0.18% / 1.31 Perf Quarter-60.92%
Sales0.00M P/S- EPS this Y11.02% Inst Trans-6.22% Short Interest0.03M Perf Half Y-63.73%
Book/sh1.91 P/B0.58 EPS next Y5.50% ROA-69.04% Target Price9.67 Perf Year-59.19%
Cash/sh2.17 P/C0.51 EPS next 5Y- ROE-90.85% 52W Range1.07 - 4.92 Perf YTD-58.74%
Dividend- P/FCF- EPS past 5Y- ROI-133.33% 52W High-77.44% Beta-0.11
Dividend %- Quick Ratio3.81 Sales past 5Y0.00% Gross Margin- 52W Low4.23% ATR0.24
Employees89 Current Ratio3.81 Sales Q/Q- Oper. Margin0.00% RSI (14)27.58 Volatility12.37% 17.86%
OptionableNo Debt/Eq0.27 EPS Q/Q15.76% Profit Margin- Rel Volume1.72 Prev Close1.18
ShortableYes LT Debt/Eq0.16 EarningsNov 09 AMC Payout- Avg Volume19.24K Price1.11
Recom1.25 SMA20-34.17% SMA50-41.87% SMA200-58.75% Volume33,170 Change-6.33%
Date Action Analyst Rating Change Price Target Change
Dec-21-22Initiated Chardan Capital Markets Buy $7
Jan-10-22Initiated H.C. Wainwright Buy $36
Nov-16-21Initiated Raymond James Outperform $31
Nov-16-21Initiated Morgan Stanley Overweight $32
Nov-16-21Initiated Guggenheim Buy $40
Nov-16-21Initiated Cowen Outperform
Nov-09-23 04:01PM
Nov-03-23 12:00PM
Oct-31-23 09:15AM
Sep-27-23 05:02PM
Sep-05-23 08:30AM
07:30AM Loading…
Aug-18-23 04:27AM
Aug-14-23 07:30AM
Aug-03-23 04:05PM
May-25-23 05:01PM
May-09-23 07:30AM
Apr-03-23 04:05PM
Mar-02-23 04:05PM
Feb-27-23 07:30AM
Feb-16-23 07:30AM
07:30AM Loading…
Feb-02-23 07:30AM
Jan-26-23 05:30AM
Jan-25-23 09:45AM
Nov-23-22 07:30AM
Nov-09-22 07:30AM
Nov-04-22 07:30AM
Sep-22-22 04:05PM
Sep-15-22 04:05PM
Sep-06-22 04:05PM
Aug-11-22 09:41AM
Aug-09-22 07:30AM
Jun-16-22 07:30AM
May-18-22 07:30AM
May-17-22 07:30AM
May-12-22 07:30AM
06:30AM Loading…
Apr-07-22 06:30AM
Mar-01-22 06:30AM
Feb-28-22 06:30AM
Feb-07-22 05:38PM
Feb-03-22 06:30AM
Jan-25-22 10:27AM
Jan-20-22 07:30AM
Jan-06-22 07:30AM
Dec-02-21 07:30AM
Nov-12-21 07:00AM
Oct-27-21 07:45AM
Oct-26-21 04:05PM
Xilio Therapeutics, Inc. operates as a biotechnology company. It focuses on harnessing the immune system to achieve deep and durable clinical responses in cancer. The company uses its proprietary geographically precise solutions platform to rapidly engineer novel molecules, including cytokines and other biologics. Xilio Therapeutics was founded by John C. Williams and Ulrich Rodeck in June 2015 and is headquartered in Waltham, MA.